Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) – Stock analysts at Cantor Fitzgerald boosted their FY2021 earnings per share estimates for shares of Cyclerion Therapeutics in a research note issued to investors on Tuesday, November 23rd. Cantor Fitzgerald analyst P. Stavropoulos now forecasts that the company will post earnings per share of ($1.36) for the year, up from their prior forecast of ($1.70). Cantor Fitzgerald has a “Overweight” rating and a $7.00 price objective on the stock. Cantor Fitzgerald also issued estimates for Cyclerion Therapeutics’ FY2022 earnings at ($1.18) EPS.
Cyclerion Therapeutics (NASDAQ:CYCN) last posted its earnings results on Tuesday, November 9th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.35) by $0.09. Cyclerion Therapeutics had a negative return on equity of 104.73% and a negative net margin of 1,696.27%.
NASDAQ:CYCN opened at $2.65 on Thursday. The stock’s fifty day moving average price is $2.81 and its two-hundred day moving average price is $3.16. Cyclerion Therapeutics has a 1 year low of $2.08 and a 1 year high of $6.90.
Several hedge funds have recently modified their holdings of the stock. Jane Street Group LLC purchased a new stake in shares of Cyclerion Therapeutics in the third quarter worth $51,000. Two Sigma Advisers LP raised its position in shares of Cyclerion Therapeutics by 98.4% in the third quarter. Two Sigma Advisers LP now owns 647,700 shares of the company’s stock worth $1,988,000 after buying an additional 321,200 shares in the last quarter. Two Sigma Investments LP raised its position in shares of Cyclerion Therapeutics by 154.1% in the third quarter. Two Sigma Investments LP now owns 390,596 shares of the company’s stock worth $1,199,000 after buying an additional 236,896 shares in the last quarter. Morgan Stanley raised its position in shares of Cyclerion Therapeutics by 6.2% in the third quarter. Morgan Stanley now owns 74,508 shares of the company’s stock worth $229,000 after buying an additional 4,353 shares in the last quarter. Finally, Eversept Partners LP purchased a new stake in shares of Cyclerion Therapeutics in the third quarter worth $1,142,000. Institutional investors own 65.21% of the company’s stock.
About Cyclerion Therapeutics
Cyclerion Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of treatments for serious and orphan diseases, through the use of soluble guanylate cyclase (sGC) pharmacology. Its product pipeline includes several sGC stimulators, a small molecules that act synergistically with nitric oxide on sGC to boost production of cyclic guanosine monophosphate (cGMP).
Further Reading: Dividend Aristocrat Index
Receive News & Ratings for Cyclerion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclerion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.